AIRS.NASDAQAirsculpt Technologies, INC
10-Q: AirSculpt Technologies Reports Q3 2024 Results: Revenue Declines Amidst Broader Market Weakness
Sentiment:
Quarterly Report
AirSculpt Technologies experienced a revenue decrease in the third quarter of 2024, primarily due to weaker performance in the aesthetics and high-end retail sectors.
Worse than expectedThe company's revenue, case volume, and revenue per case all decreased compared to the same period last year.The company's net loss increased significantly compared to the same period last year.The company's adjusted EBITDA decreased compared to the same period last year.
Summary
- AirSculpt Technologies reported a revenue of $42.5 million for the third quarter of 2024, a decrease of 9.1% compared to $46.8 million in the same period of 2023.
- The company performed 3,277 cases in Q3 2024, down from 3,426 cases in Q3 2023.
- Revenue per case also decreased to $12,984 in Q3 2024 from $13,658 in Q3 2023.
- For the nine months ended September 30, 2024, revenue was $141.2 million, a 4.8% decrease compared to $148.3 million in the same period of 2023.
- The company's net loss for Q3 2024 was $6.04 million, compared to a net loss of $1.67 million in Q3 2023.
- The net loss for the nine months ended September 30, 2024 was $3.2 million, compared to a net income of $0.1 million in the same period of 2023.
- Adjusted EBITDA for Q3 2024 was $4.7 million, down from $9.1 million in Q3 2023.
- The company opened four new centers in Q3 2024, bringing the total to 31 centers across 20 states, Canada, and the United Kingdom.
Sentiment
Score: 3
Explanation: The document presents a negative outlook due to decreased revenue, increased losses, and declining profitability. While the company is expanding, the financial performance is concerning.
Positives
- The company expanded its footprint by opening four new centers in Q3 2024.
- The company is in compliance with all debt covenants.
- The company has $5 million available on its revolving credit facility.
Negatives
- Revenue decreased by 9.1% in Q3 2024 compared to the same period in 2023.
- The number of cases performed decreased by 4.3% in Q3 2024.
- Revenue per case declined by 4.9% in Q3 2024.
- The company reported a net loss of $6.04 million for Q3 2024, a significant increase from the $1.67 million loss in Q3 2023.
- Adjusted EBITDA decreased to $4.7 million in Q3 2024 from $9.1 million in Q3 2023.
- Same-center revenue declined by 8.1% in Q3 2024.
Risks
- The company faces increased competition in the weight loss and obesity solutions market, including the impact of new weight-loss drugs.
- There are risks associated with opening and operating new centers in a timely and cost-effective manner.
- Rising interest rates and inflation could impact the company's ability to open new centers and increase operating expenses.
- The company is subject to litigation and medical malpractice claims.
- There are risks related to protecting the confidentiality of proprietary information.
- Changes in laws governing the corporate practice of medicine or fee-splitting could impact the business.
- Macroeconomic conditions, including inflation and the threat of recession, could affect the company's performance.
- Business disruptions from war, pandemics, terrorist acts, or political unrest could negatively impact the company.
Future Outlook
The company's future results could be affected by various factors, including the ability to open new centers, competition, supply chain issues, litigation, and macroeconomic conditions. The company is under no obligation to update forward-looking statements.
Management Comments
- Management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures.
- Management considers Adjusted EBITDA and Adjusted Net Income each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis.
Industry Context
The company's performance is being impacted by broader weakness in the aesthetics and high-end retail industries, suggesting a potential industry-wide slowdown. The company also faces increased competition in the weight loss and obesity solutions market, particularly from new weight-loss drugs.
Comparison to Industry Standards
- The decline in same-store revenue suggests that AirSculpt is underperforming compared to industry benchmarks, as the company is experiencing a decline in revenue while other companies in the aesthetics industry may be experiencing growth or stability.
- The company's customer acquisition costs have increased to $3,095 per customer in the nine months ended September 30, 2024, compared to $2,400 in the same period of 2023, indicating a potential inefficiency in marketing spend compared to industry standards.
- The company's adjusted EBITDA margin of 13.4% for the nine months ended September 30, 2024, is lower than the 22.3% margin in the same period of 2023, suggesting a decline in profitability compared to previous performance and potentially compared to industry peers.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Interim Chief Executive Officer | NA | Dennis Dean | NA | NA |
| Chief Financial Officer | NA | Dennis Dean | NA | NA |
| Chief Accounting Officer | NA | Philip Bodie | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Stockholders Agreement | The Stockholders Agreement was amended on July 30, 2024. | July 30, 2024 | The amendment may have altered the rights and obligations of the parties involved. |
| Amendment to Credit Agreement | The Credit Agreement was amended on September 13, 2024, to modify certain financial condition covenants. | September 13, 2024 | The amendment modified the applicable per annum margin based on the company's total leverage ratio. |
Legal Proceedings
- The company is involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice.
- A potential litigation matter outside of the company's normal course of business became probable and estimable of settlement in the third quarter of 2024, resulting in an accrual of $0.9 million in other current liabilities.
Stakeholder Impact
- Shareholders may be concerned about the decreased revenue, increased losses, and declining profitability.
- Employees may be affected by the company's performance and any potential cost-cutting measures.
- Customers may be impacted by any changes in the company's services or pricing.
- Creditors may be concerned about the company's ability to meet its debt obligations.
Next Steps
- The company will continue to monitor the impact of macroeconomic conditions and competition on its business.
- The company will continue to invest in sales and marketing capabilities as it adds new centers.
- The company will perform its annual review of goodwill impairment in October 2024.
Key Dates
| Date | Description |
|---|---|
| November 2, 2021 | Date of the original Stockholders Agreement. |
| October 28, 2021 | AirSculpt completed its initial public offering (IPO). |
| November 7, 2022 | The company entered into a credit agreement with a syndicate of lenders. |
| September 29, 2023 | The company voluntarily pre-paid $10.0 million of the principal balance of the term loans. |
| July 30, 2024 | Date of amendment to the Stockholders Agreement. |
| September 13, 2024 | The company amended the Credit Agreement to modify certain financial condition covenants. |
| September 30, 2024 | End of the reporting period for the quarterly results. |
| November 7, 2024 | Date used for the number of shares of common stock outstanding. |
| November 8, 2024 | Date of the report and the number of centers the company operates. |
Keywords
AirSculpt, body contouring, liposuction, aesthetics, revenue, EBITDA, net loss, medical procedures, financial results, healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.